MONROVIA, Calif., Nov. 5, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that a preclinical study of Xencor's bispecific CD38xCD3 program will be featured in a presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition in December. The preclinical data support further development of Xencor's CD38xCD3 bispecific antibodies in multiple myeloma and other CD38+ malignancies. "To exploit a T cell immunotherapy mechanism while retaining the favorable drug properties of therapeutic...
↧